Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - April 2025

Vendors are growing, and product and service offerings are expanding.

The Hot Market for Cold Chain Services

How artificial intelligence tools are helping to optimize the pharmaceutical transport process.

An AI-Pharma Transport Collaboration

How pharma manufacturers can steadily navigate GTN components and complexities when planning pharmacy benefit reimbursement.

Popping the Gross-to-Net Bubble, Part III: The Pharmacy Benefit

Articles

In an exclusive sit-down with Pharma Commerce, Anne Cassity, senior vice president of government affairs for the National Community Pharmacists Association (NCPA), discusses pending legislation that could affect the impact of PBM pricing. 

Limiting the Use of Spread Pricing

Videos

In the second part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, outlines strategies that companies can adopt to help mitigate these increasing costs.

How to Manage Rising Drug Development Costs

Pharma Pulse 5/16/25: A Closer Look at NIH Grant Terminations; Simulated Pre-Launch Market Evaluation in the Modern Pharmaceutical Industry

Ruth Beadle, head, global supply chain, Sanofi, explains how the company balances daily operations with long-term transformation efforts to ensure timely delivery of critical medications to patients.

LogiPharma Europe 2025: Inside the Daily Workflow of Sanofi’s Global Supply Chain Head

A qualitative study aimed to strengthen systematic repurposing efforts within rare disease nonprofit organizations, while also providing a framework for data-driven drug repurposing.

Themes Among Rare Disease Repurposing Efforts

Pharma Pulse 5/15/25: Five Questions on Trump’s Plan to Lower US Drug Prices; Roche Reports Final Overall Survival Outcomes from Breast Cancer Treatment Trial

In the first part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, shares the key factors that he believes are propelling a continued rise in projected R&D ROI.  

The Positive Momentum Behind Pharma Innovation

Andrew Witty resigns due to personal reasons, as Stephen Hemsley, chairman and former chief executive, will assume the position.

UnitedHealth Group CEO Departs

Pharma Pulse 5/14/25: Bluebird Bio Warns of Potential Bankruptcy as Buyout Faces Another Delay; Pharmacists Stockpile Most Common Drugs on Chance of Targeted Trump Tariffs

Trump anticipates that the executive order will help lower drug prices by 30% to 80%.

Featured Content

Pharmaceutical Commerce - April 2025

The Hot Market for Cold Chain Services

An AI-Pharma Transport Collaboration

Popping the Gross-to-Net Bubble, Part III: The Pharmacy Benefit